



Nuclea Biomarkers, LLC
105 South Street
Pittsfield, MA 01201
Phone 413-749-4705
Fax: 413-445-9930
Email: pr@nucleabiomarkers.com
www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE**NUCLEA BIOMARKERS ESTABLISHES RESEARCH COLLABORATION WITH
DANA FARBER CANCER INSTITUTE**

*Research Initiative Using Multi Spectral Imaging Techniques and Nuclea's Proprietary
Technology*

Pittsfield, Massachusetts ----- August 10th, 2006 ----- Nuclea Biomarkers, LLC announced today that it has signed an agreement with Dana Farber Cancer Institute (DFCI) to collaborate in research using Multi Spectral Imaging Techniques in the Oncology field. The collaboration will involve Massimo Loda, MD, a Pathologist and Researcher in the Adult Oncology Research Unit of DFCI and will utilize Multi Spectral Imaging techniques to identify certain genes and proteins that are involved in tumor formation, progression and metastasis.

Dr. Loda will utilize Nuclea Biomarker's Proprietary Tyrosine Kinase Antibody and Microfluidic Technologies (US Patents Pending) in conjunction with Multi Spectral Imaging techniques. Dr. Loda is a recognized expert in new biomarker antibody development and characterization. This collaboration will provide a powerful "toolbox" of unique technologies to further progress the understanding of the biology of how tumors develop.

"We are very excited about this collaboration with Dr. Loda's research group" states Patrick Muraca, President and CEO. "The research will yield valuable insight into the formation, progression and metastasis of both Colon and Prostate Cancer in humans and will also allow a vehicle for Nuclea to develop new products within the Tyrosine Kinase pathway", Muraca states.

DRAFT – Not For Distribution
CONFIDENTIAL

The term of the collaboration between Nuclea Biomarkers and DFCI is for twelve (12) months with an option to renew the agreement for an additional twelve (12) months.

Nuclea Biomarkers, LLC - Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research. Using the Company's extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.

Dana Farber Cancer Institute - The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases.

Dr. Loda received his MD in 1980 from the University of Milan, Italy, and his training in pathology at New England Deaconess Hospital. Following six years as a staff pathologist and researcher at Beth Israel Deaconess Medical Center, he joined DFCI in 1998. He is currently a staff pathologist at Brigham and Women's Hospital and the scientific director of the In Situ Hybridization and the Human Prostate Cancer Core Facilities, which serve all Harvard-affiliated investigators.

Multi Spectral Imaging - Spectral imaging microscopy represents a technological advance over visual or RGB-camera-based analyses, providing images at multiple wavelengths and generating precise optical spectra at every pixel, and enabling applications in surgical pathology, multicolor fluorescence and immunohistochemistry. A variety of technologies are now available for use in combination with microscopy, including tunable filters, Fourier-transform interferometry, line-scanning prism or gratings-based devices, computed tomography, and others based on polarization effects. Some of these will be discussed in greater detail, below. Mathematical approaches to these rich data sets may then be used to extract maximum possible information from the resulting data; this is an exciting and rapidly developing area of investigation.

DRAFT – Not For Distribution
CONFIDENTIAL

Nuclea Biomarkers Technology - KINASE PEPTIDES AND ANTIBODIES

The invention relates to kinase peptides and antibodies, as well as nucleic acids related to these peptides and antibodies. The present invention provides kinase peptides, antibodies, and related nucleic acids. The present invention also provides diagnostic and therapeutic compositions and methods using these peptides, antibodies and nucleic acids.

USPTO Serial Number 60-682,115

MICROFLUIDIC TECHNOLOGY - ANTIBODY PROTEIN ANALYSIS CHIP

In an embodiment, a microfluidic chip for protein analysis is disclosed wherein the microfluidic chip comprises a substrate wherein the substrate comprises a conductive material, a loading channel produced in the substrate wherein a sample may be added to the microfluidic chip and a main channel having a desired configuration wherein the main channel runs from the loading reservoir to an outlet channel. In an embodiment, the microfluidic chip comprises a plurality of side channels engaged to the main channel wherein the side channel extends from the main channel to a well. In an embodiment, the microfluidic chip comprises an at least one antibody in communication with at least one well wherein each antibody is capable of binding to a specified protein. USPTO Serial Number 60-682,166

This press release contains "forward-looking statements," including statements about the Company's growth, future operating results, discovery, development of products and strategic alliances. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; competitive factors; difficulties or delays in manufacturing the and the requirement for substantial funding to conduct research and development and to expand commercialization activities.